This study is about testing a new medicine called ONC-392, which is an antibody, a type of protein that can help fight cancer. This medicine is being tested alone and with another medicine called pembrolizumab, which is already used to treat cancer. The study focuses on advanced solid tumors and non-small cell lung cancers (NSCLC), a type of lung cancer. Patients will receive ONC-392 through an IV (intravenous) drip. The study is divided into several parts to find the best dose and to see how well it works in different kinds of cancers.
- The study includes different groups of patients with various cancers like melanoma, lung, and pancreatic cancer.
- Participants must be over 18 years old and have certain health conditions to join.
- Participants will need to visit the study site multiple times for treatment and evaluation.
Joining this study might involve risks like side effects from the treatment. However, it may also help patients who have not responded to other treatments and contribute to cancer research. Participants will need to provide informed consent to join the study.